Commonwealth Equity Services
HEPA

Commonwealth Equity Services’s Hepion Pharmaceuticals HEPA Stock Holding History

Commonwealth Equity Services’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10
Closed -$5K – 3711
2022
Q2 		$5K Hold
10
– – ﹤0.01% 3648
2022
Q1 		$12K Hold
10
– – ﹤0.01% 3682
2021
Q4 		$11K Buy
+10
New +$13.7K ﹤0.01% 3627
2021
Q2 		– Sell
-12
Closed -$21K – 3550
2021
Q1 		$21K Buy
12
+2
+20% +$4.38K ﹤0.01% 3378
2020
Q4 		$22K Buy
+10
New +$25.9K ﹤0.01% 3173

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Commonwealth Equity Services's HEPA Position: Q3 2022 in Review

Commonwealth Equity Services sold out of Hepion Pharmaceuticals (HEPA) in Q3 2022, closing a stake of 10 shares — an estimated $5K sold.

Commonwealth Equity Services first reported a position in HEPA in Q4 2020 and held it in 5 quarters. The position peaked at $22K in Q4 2020. 25 funds tracked by Wall St. Rank hold HEPA as of Q3 2022.

  • Commonwealth Equity Services reported no remaining Hepion Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Commonwealth Equity Services sold 10 Hepion Pharmaceuticals shares in Q3 2022, an estimated $5K.
  • Commonwealth Equity Services first reported a position in Hepion Pharmaceuticals in Q4 2020 and held it in 5 quarters.
  • Commonwealth Equity Services's Hepion Pharmaceuticals position peaked at $22K in Q4 2020.
  • 25 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q3 2022.

Based on Commonwealth Equity Services's 13F filing for Q3 2022, filed 14 Nov 2022.